Interview: Achilles Advances Armed With £100m
Executive Summary
After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.
You may also be interested in...
Finance Watch: Cell And Gene Therapies Buck 2019’s Venture Capital Trend
Private Company Edition: VC deals are surging this year for cell and gene therapy firms, according to ARM’s third quarter report. Also, Vivo Capital and the CF Foundation plan to invest nearly $2bn in health care and life science opportunities, and Akeso completes $150m series D.
UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’
Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.
Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs
A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma.
Need a specific report? 1000+ reports available
Buy Reports
